Ionis: Another Shot At The Commercial Market And Sustainable Profits
Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.
Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.